SCHEMBL440977

SCHEMBL440977

CC(=O)OCC(OC(C)=O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 4/20 0.39
TSHR P16473 3/20 0.39
LMNA P02545 3/20 0.39
HSD17B10 Q99714 1/20 0.39
ALOX15 P16050 1/20 0.35
CHRM2 P08172 2/20 0.34
CHRM4 P08173 2/20 0.34
CHRM1 P11229 2/20 0.34
TBXA2R P21731 2/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 1/20 0.33
GALR3 O60755 1/20 0.33
BLM P54132 1/20 0.33
PGR P06401 1/20 0.32
HTR1A P08908 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31469524 1.00 TDP1 (0.50) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL29104740 0.84 TDP1 (0.52) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL27535060 0.82 TDP1 (0.41) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL7276080 0.80 TDP1 (0.48) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL425735 0.80 TDP1 (0.48) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL6225790 0.80 TDP1 (0.48) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL13967844 0.80 TDP1 (0.48) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL1020469 0.80 TDP1 (0.48) TDP1ALDH1A1TSHRLMNAHSD17B10
SCHEMBL712304 0.80 TDP1 (0.48) TDP1ALDH1A1TSHRLMNAHSD17B10
Hydrochloric Acid SCHEMBL4305676 0.78 TDP1 (0.47) TDP1ALDH1A1TSHRLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 WO disclosed
US-20160151261-A1 STABLE COSMETIC COMPOSITION CONTAINING A MONOGLYCERIDE, A TARTARIC ESTER OF MONOGLYCERIDE, AND A COATED FILLER L'OREAL (FR) 2016-06-02 US disclosed
US-20120065227-A1 TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD SCIENCES, INC. (US) 2012-03-15 US disclosed
US-8124806-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-02-28 US disclosed
US-8124806-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-02-28 US disclosed
US-8124806-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-02-28 US disclosed
US-8088792-B2 Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-8088792-B2 Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20080260651-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2008-10-23 US disclosed
US-20080260651-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2008-10-23 US disclosed
WO-2008123779-A1 TRISUBSTITUTED TRIAZAMACROCYCLI C COMPOUNDS AND THEIR USE AS CONTRAST AGENTS GE HEALTHCARE AS (NO) 2008-10-16 WO disclosed
WO-2008123779-A1 TRISUBSTITUTED TRIAZAMACROCYCLI C COMPOUNDS AND THEIR USE AS CONTRAST AGENTS GE HEALTHCARE AS (NO) 2008-10-16 WO disclosed
WO-2007094683-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2007-08-23 WO disclosed
WO-2007094683-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2007-08-23 WO disclosed
EP-0755372-A4 INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE AND METHODS OF MAKING AND USING THE SAME UNIV ALABAMA (US) 1997-09-10 EP disclosed
EP-0755372-A1 INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE AND METHODS OF MAKING AND USING THE SAME THE UNIVERSITY OF ALABAMA AT BIRMINGHAM (US) 1997-01-29 EP disclosed
WO-1995028376-A1 INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE AND METHODS OF MAKING AND USING THE SAME THE UNIVERSITY OF ALABAMA AT BIRMINGHAM (US) 1995-10-26 WO disclosed
US-5453533-A Enzyme inhibitor THE UNIVERSITY OF ALABAMA AT BIRMINGHAM (US) 1995-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065227-A1 TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS SCD, SCD5, FASN TDP1 1555/4885ALDH1A1 1275/4885TSHR 3633/4885
US-20160151261-A1 STABLE COSMETIC COMPOSITION CONTAINING A MONOGLYCERIDE, A TARTARIC ESTER OF MONOGLYCERIDE, AND A COATED FILLER MGLL, DAGLA, GLA TDP1 461/4885ALDH1A1 1774/4885TSHR 3447/4885
US-20080260651-A1 CONTRAST AGENTS IPO4, TPO, IPO11 TDP1 2931/4885ALDH1A1 3375/4885TSHR 420/4885
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF SIGLEC7, SIGLEC9, CD2BP2 TDP1 2616/4885ALDH1A1 802/4885TSHR 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.